• Publications
  • Influence
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.
Platelet inhibition with cangrelor in patients undergoing PCI.
Cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard- dose clopIDogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis.
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagerelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke.
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
The present trial, characterized by low event rates, did not observe a significant difference in net clinical outcome between 6 and 12 months of clopidogrel therapy after DES implantation, but the results of the trial must be considered in view of its premature termination and lower than expected event rates.